Although it is generally disputable on whether ESAs treatment is a benefit or harm to the progression-free and overall survival of NSCLC patients [28, 37], the results of our study confirmed the role of endogenous EPO in lung tumorigenesis and cautioned the adverse impacts of ESAs at least in a subgroup of NSCLC patients. Here, EPO is linked to non-small cell lung carcinoma.